- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07694089
Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
A Randomized Trial of Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a steroid), no routine steroid treatment, and azeliragon, a study drug that may reduce brain swelling through a different pathway. Researchers want to determine whether these alternatives can control swelling while reducing some of the side effects associated with steroid use.
Participants in this study will be randomly assigned to one of three study groups. Participants will undergo their planned brain tumor surgery and receive the treatment assigned to their group. Study procedures are the same as their routine care and include physical and neurological examinations, blood tests, MRI scans, review of medical records, and collection of tumor tissue removed during surgery (optional). Most study visits will occur during routine medical care. Participants will be followed for approximately 24 months after surgery.
연구 개요
상세 설명
This study is a randomized Phase II trial because it is designed to evaluate the preliminary efficacy, safety, and feasibility of steroid avoidance and azeliragon as alternatives to dexamethasone for perioperative cerebral edema management in high-grade glioma. The trial uses an intermediate imaging-based efficacy endpoint, enrolls a modest sample size, and is intended to identify promising strategies for subsequent confirmation in a definitive Phase III study.
The trial compares three perioperative strategies-standard dexamethasone, complete steroid avoidance, and RAGE inhibition with azeliragon-to determine their relative safety and effectiveness in controlling cerebral edema following tumor resection. In addition to edema control, the study evaluates clinical, functional, and immunologic outcomes associated with perioperative corticosteroid exposure.
Despite widespread use, dexamethasone lacks prospective evidence defining its optimal perioperative role in glioma patients. This study addresses that gap by rigorously evaluating steroid avoidance and a mechanistically targeted alternative, with the goal of improving patient outcomes while minimizing treatment-related toxicity.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Akshitkumar M Mistry, MD
- 전화번호: 502-276-5030
- 이메일: a.mistry@uoflhealth.org
연구 연락처 백업
- 이름: UofL Health Brown Cancer Center
- 전화번호: 502-562-4370
연구 장소
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- UofL Health Brown Cancer Center; University of Louisville Hospital
-
연락하다:
- UofL Health Brown Cancer Center
- 전화번호: 502-562-4370
-
Louisville, Kentucky, 미국, 40202
- UofL Health Jewish Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
Age ≥18 years at the time of screening
- Newly diagnosed supratentorial tumor with imaging characteristics consistent with high-grade glioma
- Candidate for craniotomy with planned resection of more than 50% of the contrast-enhancing tumor
- Midline shift ≤10 mm on preoperative imaging
- Limited pre-enrollment corticosteroid exposure (≤10 mg dexamethasone total and no chronic steroid use within 30 days)
- Karnofsky Performance Status ≥60
- Adequate organ function to undergo surgery and postoperative care as determined by the investigator
- Ability to provide informed consent and comply with study procedures
- Agreement to use effective contraception, when applicable
Exclusion Criteria:
Participants meeting any of the following will be excluded:
- Imaging or clinical features highly suggestive of primary CNS lymphoma or metastatic disease
- Posterior fossa tumors or lesions associated with high risk of brainstem compression
- Leptomeningeal or widely disseminated disease
- Clinical conditions requiring immediate corticosteroid therapy
- Prior exposure to high-dose corticosteroids (>10 mg dexamethasone) or chronic steroid use within 30 days
- Active systemic illness that increases surgical risk, including uncontrolled infection, coagulopathy, or severe cardiopulmonary disease
- Pregnancy or breastfeeding
- Known immunodeficiency or chronic infection requiring immunosuppressive therapy
- Use of investigational agents within 30 days or concurrent use of immunosuppressive medications not permitted by protocol
- Known hypersensitivity to azeliragon
- Inability to undergo MRI due to contraindications such as incompatible implants or severe claustrophobia
- Life expectancy less than 3 months as determined by the investigator
- Participation in another interventional clinical trial prior to initiation of standard adjuvant therapy Vulnerable Populations: This study will not enroll children, pregnant or breastfeeding individuals, or prisoners. Individuals with impaired decision-making capacity may be enrolled only when a legally authorized representative is available to provide consent in accordance with institutional and regulatory requirements.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Dexamethasone Arm
Standard dexamethasone (steroid) treatment
|
Potent FDA-approved corticosteroid
|
|
간섭 없음: No-dexamethasone Arm
No routine dexamethasone treatment
|
|
|
실험적: Azeliragon Arm
Azeliragon administered for the treatment of brain cancer and to evaluate its capability to control brain swelling around the time of surgery.
|
orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE)
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
change in peritumoral edema between the preoperative and postoperative period
기간: before the start of adjuvant chemo radiation (up to 6 weeks)
|
The primary outcome is the change in peritumoral edema between the preoperative and postoperative period.
Specifically, it is the ratio of postoperative to preoperative peritumoral edema volume, adjusted for extent of enhancing tumor removed.
This outcome is derived from MRI-based volumetric assessment and reflects the effectiveness of each perioperative strategy in controlling cerebral edema while accounting for surgical factors
|
before the start of adjuvant chemo radiation (up to 6 weeks)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Akshitkumar M Mistry, MD, UofL Health - Brown Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ROID-RAGE-HGG
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- 연구_프로토콜
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Dexamethasone에 대한 임상 시험
-
Ain Shams University완전한건설자 Spinae 평면 블록 | 수술 후 통증 | 고관절 전치환술(THA)이집트
-
Johns Hopkins All Children's Hospital아직 모집하지 않음
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)아직 모집하지 않음
-
Al Salam University모집하지 않고 적극적으로수술 후 통증 | 트리스무스 | 얼굴 붓기 | 하악 세 번째 어금니에 영향을 미쳤다이집트
-
Vanderbilt University Medical Center종료됨
-
Poznan University of Medical Sciences모병
-
Eye & ENT Hospital of Fudan UniversityShanghai Zhongshan Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital아직 모집하지 않음